The complex genetic basis of plasma triglycerides

Current Atherosclerosis Reports

Volumn 14, Issue 3, 2012, Pages 227-234

  Johansen, Christopher T ^a   Hegele, Robert A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Allelic and phenotypic spectrum; Common variants; Genetic burden; Genetic risk scores; Hyperlipoproteinemia; Hypertriglyceridemia; Phenotypic heterogeneity; Pleiotropy; Rare variants; Triglycerides

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; BINDING PROTEIN; CHAPERONE; GLYCOPHOSPHATIDYLINOSITOL HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 1; INTERMEDIATE DENSITY LIPOPROTEIN; LIPASE MATURATION FACTOR 1; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALLELE; ANGPTL3 GENE; APOLIPOPROTEIN A5 GENE; APOLIPOPROTEIN B GENE; APOLIPOPROTEIN C2 GENE; ARTICLE; CARDIOVASCULAR RISK; CREB3L3 GENE; DISEASE CLASSIFICATION; GCKR GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLYCOPHOSPHATIDYLINOSITOL HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 1 GENE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPASE MATURATION FACTOR 1 GENE; LIPID METABOLISM; LIPOPROTEIN LIPASE GENE; LOSS OF FUNCTION MUTATION; NONHUMAN; PHENOTYPE; PLEIOTROPY; TRIACYLGLYCEROL BLOOD LEVEL; ZHX3 GENE;

CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; RISK FACTORS; TRIGLYCERIDES;

EID: 84861227604     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0243-2     Document Type: Article

References (37)

1. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-16. (Pubitemid 47080485)
2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299-308. (Pubitemid 47080484)
3. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31:1716-25. This is a thorough recent review addressing the evidence supporting both direct and indirect relationships between plasma TG concentration and cardiovascular disease.
4. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544-52.
5. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634-9.
6. Nordestgaard BG, Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol. 2011;22:113-22.
7. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176:1113-20. (Pubitemid 46649735)
8. Kirchgessner TG, LeBoeuf RC, Langner CA, et al. Genetic and developmental regulation of the lipoprotein lipase gene: loci both distal and proximal to the lipoprotein lipase structural gene control enzyme expression. J Biol Chem. 1989;264:1473-82. (Pubitemid 19050983)
9. LaRosa JC, Levy RI, Herbert P, et al. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun. 1970;41:57-62.
10. Charlton-Menys V, Durrington PN. Apolipoprotein A5 and hypertriglyceridemia. Clin Chem. 2005;51:295-7. (Pubitemid 40175797)
11. Peterfy M, Ben-Zeev O, Mao HZ, et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet. 2007;39:1483-7. (Pubitemid 350191343)
12. Davies BS, Beigneux AP, Fong LG, Young SG. New wrinkles in lipoprotein lipase biology. Curr Opin Lipidol. 2012;23:35-42.
13. Johansen CT, Hegele RA. Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta 2011:In press. This is a comprehensive review first describing our model for the allelic and phenotypic spectrum of plasma TG and HTG susceptibility.
14. Priore Oliva C, Pisciotta L, Li Volti G, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005;25:411-7. (Pubitemid 40189166)
15. Marcais C, Verges B, Charriere S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005;115:2862-9. (Pubitemid 41434413)
16. Priore Oliva C, Carubbi F, Schaap FG, et al. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J Intern Med. 2008;263:450-8. (Pubitemid 351342679)
17. Cefalu AB, Noto D, Arpi ML, et al. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab. 2009;94:4584-90.
18. Franssen R, Young SG, Peelman F, et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet. 2010;3:169-78.
19. Olivecrona G, Ehrenborg E, Semb H, et al. Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res. 2010;51:1535-45.
20. Coca-Prieto I, Kroupa O, Gonzalez-Santos P et al. Childhoodonset chylomicronaemia with reduced plasma lipoprotein lipase activity and mass: identification of a novel GPIHBP1 mutation. J Intern Med. 2011;270:224-8.
21. Beigneux AP, Franssen R, Bensadoun A, et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol. 2009;29:956-62.
22. Wang J, Hegele RA. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoproteinbinding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis. 2007;6:23.
23. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52:189-206.
24. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet. 2010;42:684-7.
25. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-13.
26. Johansen CT, Wang J, Lanktree MB, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2011;31:1916-26.
27. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol. 2011;22:247-53.
28. Johansen CT, Wang J, McIntyre AD et al. Excess of rare variants in non-GWAS candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet. 2012;5:66-72. This is a rare variant accumulation study implicating non-GWAS candidate genes in HTG susceptibility using novel analytical strategies.
29. Lee MW, Chanda D, Yang J, et al. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab. 2010;11:331-9.
30. Lee JH, Giannikopoulos P, Duncan SA, et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med. 2011;17:812-5.
31. Gargalovic PS, Erbilgin A, Kohannim O, et al. Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism. Circ Cardiovasc Genet. 2010;3:60-7.
32. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008;29:11-26.
33. Musunuru K, Pirruccello JP, Do R, et al. Exome Sequencing, Mutations in ANGPTL3, and Familial Combined Hypolipidemia. N Engl J Med. 2010;363:2220-7.
34. Pisciotta L, Favari E, Magnolo AL et al. Characterization of three kindreds with familial combined hypolipidemia due to loss of function mutations of ANGPTL3. Circ Cardiovasc Genet. 2012;5:42-50.
35. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70-9.
36. Romeo S, Pennacchio LA, Fu Y, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39:513-6. (Pubitemid 46514768)
37. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-5.